Selected research
Industry Research
Active Tuberculosis Treatment Industry Research Report 2026
Market perspective
The global Active Tuberculosis Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Active Tuberculosis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Active Tuberculosis Treatment is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Active Tuberculosis Treatment is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Active Tuberculosis Treatment include Teva Pharmaceutical Industries Ltd., Sanofi, Johnson & Johnson, Novartis AG, Pfizer Inc., Otsuka Pharmaceutical Co., Ltd., Macleods Pharmaceuticals Ltd., Lupin and KGaA (Fresenius Kabi), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Active Tuberculosis Treatment market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Active Tuberculosis Treatment Market by Company
Teva Pharmaceutical Industries Ltd.
Sanofi
Johnson & Johnson
Novartis AG
Pfizer Inc.
Otsuka Pharmaceutical Co., Ltd.
Macleods Pharmaceuticals Ltd.
Lupin
KGaA (Fresenius Kabi)
FRESENIUS SE & Co
ANI Pharmaceuticals, Inc.
Active Tuberculosis Treatment Segment by Type
Ethambutol
Rifampin
Pyrazinamide
Active Tuberculosis Treatment Segment by Application
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Pharmacies
Active Tuberculosis Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Active Tuberculosis Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Active Tuberculosis Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Active Tuberculosis Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Active Tuberculosis Treatment manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Active Tuberculosis Treatment by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Active Tuberculosis Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Ethambutol
- Rifampin
- Pyrazinamide
Applications
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Pharmacies
Companies covered
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Johnson & Johnson
- Novartis AG
- Pfizer Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Macleods Pharmaceuticals Ltd.
- Lupin
- KGaA (Fresenius Kabi)
- FRESENIUS SE & Co
- ANI Pharmaceuticals, Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Active Tuberculosis Treatment Market Size (2021-2032)
- 2.2.2 Global Active Tuberculosis Treatment Sales (2021-2032)
- 2.2.3 Global Active Tuberculosis Treatment Market Average Price (2021-2032)
- 2.3 Active Tuberculosis Treatment by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Ethambutol
- 2.3.3 Rifampin
- 2.3.4 Pyrazinamide
- 2.4 Active Tuberculosis Treatment by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital Pharmacies
- 2.4.3 Drug Stores and Retail Pharmacies
- 2.4.4 Online Pharmacies
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Active Tuberculosis Treatment Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Active Tuberculosis Treatment Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Active Tuberculosis Treatment Revenue of Manufacturers (2021-2026)
- 3.4 Global Active Tuberculosis Treatment Average Price by Manufacturers (2021-2026)
- 3.5 Global Active Tuberculosis Treatment Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Active Tuberculosis Treatment, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Active Tuberculosis Treatment, Product Type & Application
- 3.8 Global Manufacturers of Active Tuberculosis Treatment, Established Date
- 3.9 Global Active Tuberculosis Treatment Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva Pharmaceutical Industries Ltd.
- 4.1.1 Teva Pharmaceutical Industries Ltd. Company Information
- 4.1.2 Teva Pharmaceutical Industries Ltd. Business Overview
- 4.1.3 Teva Pharmaceutical Industries Ltd. Active Tuberculosis Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Pharmaceutical Industries Ltd. Active Tuberculosis Treatment Product Portfolio
- 4.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments
- 4.2 Sanofi
- 4.2.1 Sanofi Company Information
- 4.2.2 Sanofi Business Overview
- 4.2.3 Sanofi Active Tuberculosis Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sanofi Active Tuberculosis Treatment Product Portfolio
- 4.2.5 Sanofi Recent Developments
- 4.3 Johnson & Johnson
- 4.3.1 Johnson & Johnson Company Information
- 4.3.2 Johnson & Johnson Business Overview
- 4.3.3 Johnson & Johnson Active Tuberculosis Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Johnson & Johnson Active Tuberculosis Treatment Product Portfolio
- 4.3.5 Johnson & Johnson Recent Developments
- 4.4 Novartis AG
- 4.4.1 Novartis AG Company Information
- 4.4.2 Novartis AG Business Overview
- 4.4.3 Novartis AG Active Tuberculosis Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Novartis AG Active Tuberculosis Treatment Product Portfolio
- 4.4.5 Novartis AG Recent Developments
- 4.5 Pfizer Inc.
- 4.5.1 Pfizer Inc. Company Information
- 4.5.2 Pfizer Inc. Business Overview
- 4.5.3 Pfizer Inc. Active Tuberculosis Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Pfizer Inc. Active Tuberculosis Treatment Product Portfolio
- 4.5.5 Pfizer Inc. Recent Developments
- 4.6 Otsuka Pharmaceutical Co., Ltd.
- 4.6.1 Otsuka Pharmaceutical Co., Ltd. Company Information
- 4.6.2 Otsuka Pharmaceutical Co., Ltd. Business Overview
- 4.6.3 Otsuka Pharmaceutical Co., Ltd. Active Tuberculosis Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Otsuka Pharmaceutical Co., Ltd. Active Tuberculosis Treatment Product Portfolio
- 4.6.5 Otsuka Pharmaceutical Co., Ltd. Recent Developments
- 4.7 Macleods Pharmaceuticals Ltd.
- 4.7.1 Macleods Pharmaceuticals Ltd. Company Information
- 4.7.2 Macleods Pharmaceuticals Ltd. Business Overview
- 4.7.3 Macleods Pharmaceuticals Ltd. Active Tuberculosis Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Macleods Pharmaceuticals Ltd. Active Tuberculosis Treatment Product Portfolio
- 4.7.5 Macleods Pharmaceuticals Ltd. Recent Developments
- 4.8 Lupin
- 4.8.1 Lupin Company Information
- 4.8.2 Lupin Business Overview
- 4.8.3 Lupin Active Tuberculosis Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Lupin Active Tuberculosis Treatment Product Portfolio
- 4.8.5 Lupin Recent Developments
- 4.9 KGaA (Fresenius Kabi)
- 4.9.1 KGaA (Fresenius Kabi) Company Information
- 4.9.2 KGaA (Fresenius Kabi) Business Overview
- 4.9.3 KGaA (Fresenius Kabi) Active Tuberculosis Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 KGaA (Fresenius Kabi) Active Tuberculosis Treatment Product Portfolio
- 4.9.5 KGaA (Fresenius Kabi) Recent Developments
- 4.10 FRESENIUS SE & Co
- 4.10.1 FRESENIUS SE & Co Company Information
- 4.10.2 FRESENIUS SE & Co Business Overview
- 4.10.3 FRESENIUS SE & Co Active Tuberculosis Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 FRESENIUS SE & Co Active Tuberculosis Treatment Product Portfolio
- 4.10.5 FRESENIUS SE & Co Recent Developments
- 4.11 ANI Pharmaceuticals, Inc.
- 4.11.1 ANI Pharmaceuticals, Inc. Company Information
- 4.11.2 ANI Pharmaceuticals, Inc. Business Overview
- 4.11.3 ANI Pharmaceuticals, Inc. Active Tuberculosis Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 ANI Pharmaceuticals, Inc. Active Tuberculosis Treatment Product Portfolio
- 4.11.5 ANI Pharmaceuticals, Inc. Recent Developments
5 Global Active Tuberculosis Treatment Market Scenario by Region
- 5.1 Global Active Tuberculosis Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Active Tuberculosis Treatment Sales by Region: 2021-2032
- 5.2.1 Global Active Tuberculosis Treatment Sales by Region: 2021-2026
- 5.2.2 Global Active Tuberculosis Treatment Sales by Region: 2027-2032
- 5.3 Global Active Tuberculosis Treatment Revenue by Region: 2021-2032
- 5.3.1 Global Active Tuberculosis Treatment Revenue by Region: 2021-2026
- 5.3.2 Global Active Tuberculosis Treatment Revenue by Region: 2027-2032
- 5.4 North America Active Tuberculosis Treatment Market Facts & Figures by Country
- 5.4.1 North America Active Tuberculosis Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Active Tuberculosis Treatment Sales by Country (2021-2032)
- 5.4.3 North America Active Tuberculosis Treatment Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Active Tuberculosis Treatment Market Facts & Figures by Country
- 5.5.1 Europe Active Tuberculosis Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Active Tuberculosis Treatment Sales by Country (2021-2032)
- 5.5.3 Europe Active Tuberculosis Treatment Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Active Tuberculosis Treatment Market Facts & Figures by Country
- 5.6.1 Asia Pacific Active Tuberculosis Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Active Tuberculosis Treatment Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Active Tuberculosis Treatment Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Active Tuberculosis Treatment Market Facts & Figures by Country
- 5.7.1 South America Active Tuberculosis Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Active Tuberculosis Treatment Sales by Country (2021-2032)
- 5.7.3 South America Active Tuberculosis Treatment Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Active Tuberculosis Treatment Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Active Tuberculosis Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Active Tuberculosis Treatment Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Active Tuberculosis Treatment Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Active Tuberculosis Treatment Sales by Type (2021-2032)
- 6.1.1 Global Active Tuberculosis Treatment Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Active Tuberculosis Treatment Sales Market Share by Type (2021-2032)
- 6.2 Global Active Tuberculosis Treatment Revenue by Type (2021-2032)
- 6.2.1 Global Active Tuberculosis Treatment Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Active Tuberculosis Treatment Revenue Market Share by Type (2021-2032)
- 6.3 Global Active Tuberculosis Treatment Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Active Tuberculosis Treatment Sales by Application (2021-2032)
- 7.1.1 Global Active Tuberculosis Treatment Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Active Tuberculosis Treatment Sales Market Share by Application (2021-2032)
- 7.2 Global Active Tuberculosis Treatment Revenue by Application (2021-2032)
- 7.2.1 Global Active Tuberculosis Treatment Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Active Tuberculosis Treatment Revenue Market Share by Application (2021-2032)
- 7.3 Global Active Tuberculosis Treatment Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Active Tuberculosis Treatment Value Chain Analysis
- 8.1.1 Active Tuberculosis Treatment Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Active Tuberculosis Treatment Production Mode & Process
- 8.2 Active Tuberculosis Treatment Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Active Tuberculosis Treatment Distributors
- 8.2.3 Active Tuberculosis Treatment Customers
9 Global Active Tuberculosis Treatment Analyzing Market Dynamics
- 9.1 Active Tuberculosis Treatment Industry Trends
- 9.2 Active Tuberculosis Treatment Industry Drivers
- 9.3 Active Tuberculosis Treatment Industry Opportunities and Challenges
- 9.4 Active Tuberculosis Treatment Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst